Allen Mooney & Barnes Investment Advisors LLC Sells 5,137 Shares of Pfizer Inc. (NYSE:PFE)

Allen Mooney & Barnes Investment Advisors LLC trimmed its position in shares of Pfizer Inc. (NYSE:PFEFree Report) by 15.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 28,753 shares of the biopharmaceutical company’s stock after selling 5,137 shares during the quarter. Allen Mooney & Barnes Investment Advisors LLC’s holdings in Pfizer were worth $828,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Bonness Enterprises Inc. lifted its position in Pfizer by 4.6% in the 4th quarter. Bonness Enterprises Inc. now owns 114,708 shares of the biopharmaceutical company’s stock valued at $3,302,000 after acquiring an additional 5,000 shares in the last quarter. Secure Asset Management LLC lifted its position in Pfizer by 1.2% in the 4th quarter. Secure Asset Management LLC now owns 48,795 shares of the biopharmaceutical company’s stock valued at $1,405,000 after acquiring an additional 577 shares in the last quarter. Bellecapital International Ltd. lifted its position in Pfizer by 41.3% in the 4th quarter. Bellecapital International Ltd. now owns 46,123 shares of the biopharmaceutical company’s stock valued at $1,328,000 after acquiring an additional 13,491 shares in the last quarter. Argus Investors Counsel Inc. lifted its position in Pfizer by 17.2% in the 4th quarter. Argus Investors Counsel Inc. now owns 43,315 shares of the biopharmaceutical company’s stock valued at $1,247,000 after acquiring an additional 6,350 shares in the last quarter. Finally, Caldwell Sutter Capital Inc. lifted its position in Pfizer by 3.1% in the 4th quarter. Caldwell Sutter Capital Inc. now owns 71,947 shares of the biopharmaceutical company’s stock valued at $2,071,000 after acquiring an additional 2,153 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently commented on PFE. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Monday. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a research report on Thursday, January 4th. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Barclays cut their price target on shares of Pfizer from $34.00 to $28.00 and set an “equal weight” rating on the stock in a research report on Thursday, December 14th. Finally, UBS Group cut their price target on shares of Pfizer from $34.00 to $27.00 and set a “neutral” rating on the stock in a research report on Thursday, December 14th. Twelve research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $36.88.

Get Our Latest Stock Report on PFE

Pfizer Stock Down 0.2 %

Pfizer stock opened at $27.70 on Tuesday. Pfizer Inc. has a fifty-two week low of $25.61 and a fifty-two week high of $42.22. The firm has a market capitalization of $156.85 billion, a PE ratio of 76.94, a P/E/G ratio of 1.24 and a beta of 0.61. The company’s 50-day moving average is $27.44 and its 200-day moving average is $29.34. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69.

Pfizer (NYSE:PFEGet Free Report) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. During the same quarter in the prior year, the business earned $1.14 EPS. Pfizer’s quarterly revenue was down 41.3% on a year-over-year basis. Sell-side analysts anticipate that Pfizer Inc. will post 2.22 earnings per share for the current year.

Pfizer Company Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Stories

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.